DUHS launches tool for infectious-disease care
‘Bug & Drug’ aims to support evidence-based treatment and responsible antibiotic use
IV Report
KARACHI: The Dow University of Health Sciences
(DUHS) has launched a locally developed clinical decision-support application
aimed at helping doctors make evidence-based decisions in the treatment of
infectious diseases, with its developers and health experts also highlighting
its potential role in promoting responsible antibiotic use and addressing
antimicrobial resistance (AMR).
The “Bug & Drug” application was formally launched
by DUHS Vice Chancellor Prof Nazli Hossain at the auditorium of the Sindh
Infectious Diseases Hospital & Research Centre (SIDH&RC), while former
DUHS vice chancellor Prof Muhammad Saeed Quraishy inaugurated its publication.
Addressing the ceremony, Prof Saeed Quraishy said
recurrent infections remained an important clinical challenge and expressed the
hope that the application would be widely utilised by healthcare professionals.
He also acknowledged the need for practical tools that could support clinicians
dealing with infectious diseases and complex treatment decisions.
In such circumstances, she said, the application could
provide doctors with evidence-based guidance at the bedside. She stressed,
however, that the tool should be regularly updated according to data generated
by local hospitals.
Prof Hossain suggested that a short tutorial on its use
be made available on the university's website to facilitate wider adoption. She
also highlighted its possible application in conditions including puerperal
sepsis and said its role in secondary-care hospitals should be explored.
Explaining the concept behind the application, Dr Muneeba
Ahsan Saeed said its name reflected its basic purpose — identifying the
infectious organism, or “Bug”, and selecting the appropriate “Drug”. The
application contains information on 113 infectious diseases, 141 aetiological
agents and 75 antimicrobials, she said.
The developers emphasised that the application had been
designed according to Pakistan's medical and local context while incorporating
international standards. Dr Muneeba Ahsan Saeed and Dr Fizza Farooqi said its
purpose was to support, rather than replace, specialist clinical judgement.
The public-health significance of such support lies
partly in the appropriate use of antibiotics. Unnecessary or inappropriate
antimicrobial treatment contributes to the development and spread of resistant
organisms, while delays in treating serious infections can increase the risk of
complications. Antibiotic selection and dosing may also need to take account of
the suspected organism, culture results, antimicrobial susceptibility and
individual patient factors.
During a demonstration, the developers showed features
intended to assist clinicians with these decisions. The application includes a
Quick ID Consult and a Creatinine Clearance calculator, while the NEWS2 tool
helps assess a patient's clinical risk. The application also provides guidance
on when antibiotics should be initiated in cases of sepsis.
Another section deals specifically with AMR, providing
information on resistant organisms, associated resistance genes and possible
treatment options.
Prof Dr Syed Faisal Mahmood described infectious
diseases as a complex area in which clinical decisions could be difficult
because of the wide range of microorganisms, antimicrobial choices and
patient-specific considerations. He said the application had been developed
with local organisms, diseases and available medicines in mind, distinguishing
it from international reference resources that may not be specifically tailored
to Pakistan.
He encouraged healthcare professionals to use the
application and provide feedback so that it could be improved.
He also pointed to the wider dimensions of AMR, saying
inappropriate antibiotic use was not confined to human health but was connected
with animals and the environment. The declining pace of development of new
antibiotics, he added, made research increasingly important.
The app's developers said local data would therefore be
important to its future development. Prof Hossain also stressed the need to
determine whether its use should remain primarily hospital-based or eventually
draw on wider city and regional data.
Beyond antimicrobial treatment, “Bug & Drug”
includes information intended to support several areas of infectious-disease
care. Its sections cover HIV and tuberculosis treatment centres in Pakistan,
symptom-based diagnosis and management of sexually transmitted infections,
including partner management and follow-up, and vaccination information
covering schedules, administration and possible adverse effects.
Dr Asma Naseem stressed the importance of awareness and
outreach among doctors, particularly in public-sector hospitals. She said wider
use could generate both greater benefit and useful feedback for further
development.
The application also includes a bug-reporting facility
through which users can report errors, information gaps and suggestions to the
development team.
The speakers described “Bug & Drug” as an evolving
platform that could be expanded in line with local antibiograms, emerging
evidence, clinical requirements and user feedback.
At its core, the initiative reflects a broader need beyond any individual
digital tool: strengthening local evidence for infectious-disease treatment,
improving timely recognition of serious infections, and ensuring that
antimicrobial medicines are used when they are needed and in ways that help
preserve their effectiveness.




Comments
Post a Comment